Design, synthesis and biological evaluation of uncharged catechol derivatives as selective inhibitors of PTP1B
作者:Xiang-Qian Li、Qi Xu、Jiao Luo、Li-Jun Wang、Bo Jiang、Ren-Shuai Zhang、Da-Yong Shi
DOI:10.1016/j.ejmech.2017.05.007
日期:2017.8
obesity. However, the development of charged PTP1B inhibitors was restricted due to their low cell permeability and poor bioavailability. Based on active natural products, two series of uncharged catechol derivatives were identified as PTP1B inhibitors by targeting a secondary aryl phosphate-binding site as well as the catalytic site. The most potent inhibitor 22 showed an IC50 of 0.487 μM against PTP1B and
蛋白质酪氨酸磷酸酶1B(PTP1B)是有效治疗T2DM和肥胖症的有希望且经过验证的治疗靶标。但是,带电的PTP1B抑制剂由于其低的细胞渗透性和较差的生物利用度而受到限制。基于活性天然产物,通过靶向磷酸二芳基酯结合位点和催化位点,鉴定了两个系列的不带电荷的邻苯二酚衍生物为PTP1B抑制剂。最有效的抑制剂22对PTP1B的IC 50为0.487μM,相对于TCPTP具有很强的选择性(27倍)。还进行了动力学研究,发现22种可作为竞争性PTP1B抑制剂。22例C2C12肌管的治疗显着增加了IRβ,Akt和IRS1的磷酸化水平。其作用谱与胰岛素产生的相似,表明其作为一种新的非胰岛素依赖性候选药物的潜力。